• About Us

    Developing high-value products for patients in niche indications with significant unmet medical need

  • FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

  • Calliditas wins ‘Company of the Year’ at the European Mediscience Awards 2022

Vision and Strategy

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Our Pipeline

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Share Price: Sweden

Share Price: US

Interim Report Q1 2022

On May 18, 2022, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2022.

Audio cast with teleconference, Q1 2022, May 18, 2022, 14:30 CET